Comparison · NCT03265132-a234ba3c
Anakinra vs Placebo: Proportion of Patients With at Least One Adverse Event.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Anakinra vs Placebo: Proportion of Patients With at Least One Adverse Event. Trial comparisons, record NCT03265132-a234ba3c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03265132-a234ba3c
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 1 | 0.61 | 1 | wilson | |
| Risk in group 2 | 0.667 | 0.3 | 0.903 | wilson | |
| Risk difference, group 1 minus group 2 | 0.333 | -0.123 | 0.7 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.5 | 0.852 | 2.64 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on Anakinra than on Placebo | 3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Anakinra | 2 mg/kg/day (max 100 mg/day) or 4 mg/kg/day (max 200 mg/day)~anakinra: sub cutaneous injection | 6 | 6 | OG000 |
| Group 2 | Placebo | Corresponding volume to anakinra 2 mg/kg/day or 4 mg/kg/day~Placebo: sub cutaneous injection | 4 | 6 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Proportion of Patients With at Least One Adverse Event.
- Description
- All adverse events collected from start of study treatment up to 28 days after stopping study treatment.
- Time frame
- From Day 1 to Week 16
- Population
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)
- NCT number
- NCT03265132
- Phases
- PHASE3
- Conditions
- Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
- Interventions
- anakinra, Placebo
- Lead sponsor
- Swedish Orphan Biovitrum
- Results first posted
- 2020-04-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03265132?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03265132-a234ba3c